Back to Journals » OncoTargets and Therapy » Volume 12

CART cell therapy for prostate cancer: status and promise

Authors Yu H, Pan J, Guo Z, Yang C, Mao L

Received 28 August 2018

Accepted for publication 22 November 2018

Published 3 January 2019 Volume 2019:12 Pages 391—395

DOI https://doi.org/10.2147/OTT.S185556

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Sanjay Singh


Haiyuan Yu,1,* Jun Pan,1,* Zhicheng Guo,1 Chunhua Yang,1,2 Lijun Mao1,2

1Department of Urinary Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China; 2Jiangsu Key Laboratory of Biological Cancer Therapy, Department of Clinic Institute, Xuzhou Medical University, Xuzhou 221002, China

*These authors contributed equally to this work

Abstract: In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.

Keywords: prostate cancer, CAR-T cells, adoptive immunotherapy, review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]